No Data
No Data
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
TD Cowen Maintains Fate Therapeutics(FATE.US) With Hold Rating
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $8
Optimistic Outlook for Fate Therapeutics' FT819 in Cell-Therapy Space Amid Promising Phase 1 Results
MilaDing : What to collect.